RESEARCH TRIANGLE PARK, N.C., March 20 /PRNewswire/ -- Quintiles Transnational Corp. today announced that it has reached a significant milestone in data management -- the 200th clinical trial using Electronic Data Capture (EDC).
Quintiles is using EDC in a trial being conducted in the United Kingdom for Aerovance, Inc., of Berkeley, Calif., which is studying a drug candidate for chronic obstructive pulmonary disease. Quintiles began using EDC in 1999 and has seen the acceptance of EDC accelerate since then, with more than 60 EDC trials put into production in 2005.
“This achievement is important for Quintiles as well as the pharmaceutical and biotechnology industries because it indicates the increasing recognition of the tangible benefits of EDC,” said Paula Brown Stafford, Executive Vice President, Global Data Management, Quintiles. “As the leader in outsourced EDC services, we are seeing greater appreciation for the potential savings in time and expense, as well as the ability to provide better access to data throughout the length of the study.
“We are thrilled to work again with Aerovance, an emerging biopharmaceutical company that is conducting important research into serious respiratory and inflammatory diseases. Quintiles looks forward to bringing Aerovance our expertise managing electronic patient data.”
Quintiles also is conducting EDC studies for Aerovance in the treatment of cystic fibrosis, asthma and eczema.
“Quintiles Data Management has developed an elegant clinical EDC program for us,” said Richard Fuller, Chief Operating Officer, Aerovance. “We turned to Quintiles because of the good experience we had working with them before, as well as their flexibility, which allows them to work with an emerging biotech like us just as they would with a major pharmaceutical company.”
About Aerovance
Aerovance is a privately held biopharmaceutical company focused exclusively on the development and commercialization of biologics for severe respiratory and inflammatory diseases such as asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and eczema. The company’s two lead products are AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies, and AER002 a recombinant protein for CF and COPD currently in Phase 2 studies. In addition to these investigational products, Aerovance has several preclinical programs in respiratory disease. Aerovance was spun off from Bayer Pharmaceuticals’ biotechnology unit in August 2004.
About Quintiles Global Data Management
Quintiles Global Data Management delivers consistent, accurate data through flexible and cost-effective solutions for customers. Services include capturing, analyzing and reporting patient-related data traditionally, by paper and fax, or electronically, by EDC and PDA, and then integrating data into a clean, compatible and fully CDISC-compliant database to facilitate regulatory submission and acceptance. Quintiles Global Data Management has more than 1,000 employees in 10 offices around the world.
About Quintiles
Quintiles is the global leader in pharmaceutical services, improving healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of the pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000 specialized employees and offices in 50 countries. For more information visit the company’s Web site at http://www.quintiles.com.
Quintiles Transnational Corp.
CONTACT: Dick Jones, Media Relations, +1-919-998-2091, ormedia.info@quintiles.com, or Greg Connors, Investor Relations,+1-919-998-2000, or invest@quintiles.com, both of Quintiles TransnationalCorp.
Web site: http://www.quintiles.com/
